Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia

Thrombosis Research

Volumn 96, Issue 3, 1999, Pages 191-196

  Griesshammer, M ^a   Beneke, H ^a   Nussbaumer, B ^a   Grunewald M ^a   Bangerter, M ^a   Bergmann, L ^a  

^a Dept of Haematology and Oncology   (Germany)

Author keywords

Essential thrombocythaemia; P selectin (CD62p); Platelet activation; Thrombospondin

Indexed keywords

ACETYLSALICYLIC ACID; PADGEM PROTEIN; THROMBOSPONDIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOCYTHEMIA; THROMBOEMBOLISM;

ASPIRIN; BLOOD PLATELETS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSPONDINS;

EID: 0032712186     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00095-X     Document Type: Article

References (21)

1. Griesshammer M, Bangerter M, Schrezenmeier H, Müller H, Tuner I, Seifried E, Heimpel H. Veränderungen der Thrombozyten und der Thrombozytopoese bei den chronischen myeloproliferativen Syndromen. In: Fleischer J, Hiddemann W, Hoelzer D, Editors. Therapie der Leukämien und Lymphome. Beitr Onkol. Basel: Karger; 1998. p. 152-8.
2. Schafer A.I. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N Engl J Med. 306:1982;381-386.
3. Nurden P., Bihour C., Smith M., Raymond J.M., Nurden A.T. Platelet activation and thrombosis. Studies in a patient with essential thrombocythemia Am J Hematol. 51:1996;79-84.
4. Van Genderen P.J., Lucas I.S., Van Strik R., Vuzevski V.D., Prins F.J., Van Vliet H.H., Michiels J.J. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemostas. 76:1996;333-338.
5. 2+-dependent adhesion of activated platelets to many different types of leucocytes. Detection by flow cytometry Blood. 80:1992;134-142.
6. Legrand C.H., Dubernard V., Kieffer M., Nurden A.T. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem. 171:1988;393-399.
7. Tuszynski G.P., Rothman V.L., Murphy A., Siegler K., Knudsen K.A. Thrombospondin promotes platelet aggregation. Blood. 72:1988;109-115.
8. Tschoepe D., Schauseil S., Roesen P., Kaufmann L., Gries F.A. Darstellung von Thrombozytenmembranproteinen mit monoklonalen Antikörpern im durchflusszytometrischen Bio-Assay. Klin Wochenschr. 66:1988;117-122.
9. Tschoepe D., Spangenberg P., Esser J., Schwippert B., Kehrel B., Roesen P., Gries F.A. Flow-cytometric detection of surface membrane alterations and concomitant changes in the cytoskeletal actin status of activated platelets. Cytometry. 11:1990;652-656.
10. Meetzelaar M.J., Sixma J.J., Nieuwenhuis H.K. Detection of platelet activation using activation specific monoclonal antibodies. Blood Cells. 16:1990;85-96.
11. Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia. An interim report from the Polycythaemia Vera Study Group Semin Hematol. 23:1986;177-182.
12. Tschoepe D., Roesen P., Schwippert B., Gries F.A. Platelets in diabetes. The role in the hemostatic regulation in atherosclerosis Semin Thromb Hemost. 19:1993;122-128.
13. Tschoepe D., Schultheiß H.P., Kolarov P., Schwippert B., Dannehl K., Nieuwenhuis H.K., Kehrel B., Strauer B., Gries F.A. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 88:1993;37-42.
14. Kannan K., Divers S.G., Lurie A.A., Chervenak R., Fukuda M., Holcombe R.F. Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol. 55:1995;145-151.
15. Grau A.J., Ruf A., Vogt A., Lichy C., Buggle F., Patscheke H., Hacke W. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemostas. 80:1998;298-301.
16. Gawaz M., Neumann F.J., Ott I., Schiessler A., Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 93:1996;229-237.
17. Gawaz M., Neumann F.J., Ott I., May A., Rüdiger S., Schömig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart. 76:1996;166-172.
18. Wehmeier A., Tschoepe D., Esser J., Menzel C., Nieuwenhuis H.K., Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res. 61:1991;271-278.
19. Legrand C., Bellucci S., Disdier M., Edelman L., Tobelem G. Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia. Effect of α-interferon treatment Am J Hematol. 38:1991;307-313.
20. Thibert V., Bellucci S., Edelman L., Tandon N.N., Legrand C. Quantitation of platelet glycoprotein IV (CD36) in healthy subjects and in patients with essential thrombocythemia using an immunocapture assay. Thromb Haemostas. 68:1992;600-605.
21. Finazzi G., Budde U., Michiels J.J. Bleeding time and platelet function in essential thrombocythaemia and other myeloproliferative syndromes. Leukemia and Lymphoma. 22(Suppl1):1996;71-78.